Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0000950170-25-053778·MAVERICK CAPITAL LTD
Schedule 13G ownership disclosure
Rocket Pharmaceuticals Inc
Common Stock, $0.01 par value · CUSIP: 77313F106
Event date: 2025-04-07
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Maverick Capital, Ltd.
Shares: 5,547,175 · Class: 5.2%
- Maverick Capital Management, LLC
Shares: 5,547,175 · Class: 5.2%
- Lee S. Ainslie III
Shares: 5,547,175 · Class: 5.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-053778
- Form type
- SCHEDULE 13G
- Filer
- MAVERICK CAPITAL LTD
- CIK
- CIK 934639
- Filed
- Apr 14, 2025
- Reporting period
- Apr 07, 2025
- Description
- Schedule 13G beneficial ownership